Crizotinib hydrochloride: Precision ATP-Competitive ALK, c-Met, and ROS1 Kinase Inhibition

Executive Summary: Crizotinib hydrochloride (CAS 1415560-69-8) is an orally bioavailable, ATP-competitive small molecule inhibitor targeting ALK, c-Met, and ROS1 kinases, and is validated for use in advanced cancer biology research (Shapira-Netanelov et al., 2025). It efficiently inhibits tyrosine phosphorylation of ALK and c-Met at low nanomolar concentrations in vitro. Its high solubility in DMSO, ethanol, and water enables flexible integration into cell-based and assembloid platforms (APExBIO). The compound is rigorously quality-controlled, exceeding 98% purity by HPLC/NMR. Recent studies highlight its value for dissecting tumor–stroma interactions and resistance mechanisms in patient-derived models (Shapira-Netanelov et al., 2025).

Biological Rationale

Oncogenic kinases ALK, c-Met, and ROS1 drive tumor progression in multiple cancer types, including non-small cell lung cancer (NSCLC) and gastric cancer (Shapira-Netanelov et al., 2025). Aberrant activation of these kinases results from gene rearrangements, amplifications, or overexpression, promoting uncontrolled cellular proliferation and survival. Targeted inhibition of these kinases is a validated therapeutic strategy and is crucial for preclinical research aimed at understanding resistance mechanisms and optimizing combination therapies. Crizotinib hydrochloride is widely adopted for mechanistic studies due to its selectivity and compatibility with advanced in vitro models such as assembloids and organoids (see APExBIO technical summary).

Mechanism of Action of Crizotinib hydrochloride

Crizotinib hydrochloride is an ATP-competitive inhibitor that binds to the ATP-binding pocket of ALK, c-Met, and ROS1 kinases (APExBIO). It suppresses kinase activity by preventing tyrosine phosphorylation of substrate proteins. In cell-based assays, Crizotinib hydrochloride reduces the phosphorylation status of c-Met receptors and NPM-ALK fusion proteins at concentrations in the low nanomolar range. This inhibition blocks downstream signaling cascades involved in tumor cell proliferation, migration, and survival. The compound’s selectivity profile has been confirmed in biochemical and cellular assays, with minimal off-target kinase activity at relevant concentrations. Its mechanism enables precise functional interrogation of oncogenic kinase signaling pathways in translational research (see in-depth mechanism review—this article updates kinase selectivity benchmarks).

Evidence & Benchmarks

• Crizotinib hydrochloride achieves ≥98% purity by HPLC/NMR, ensuring experimental reproducibility (APExBIO).
• It inhibits ALK and c-Met tyrosine phosphorylation in vitro at low nanomolar concentrations (typically 20–100 nM) (Shapira-Netanelov et al., 2025).
• The compound demonstrates high solubility: ≥100.4 mg/mL in DMSO, ≥101.4 mg/mL in ethanol, ≥52.2 mg/mL in water, supporting diverse assay platforms (APExBIO).
• Patient-derived gastric cancer assembloids treated with Crizotinib hydrochloride reveal drug-specific and patient-specific response variability, highlighting its utility in personalized research (Shapira-Netanelov et al., 2025).
• The use of Crizotinib hydrochloride in co-culture assembloid systems has enabled the identification of tumor–stroma-driven drug resistance mechanisms, not observable in monocultures (Shapira-Netanelov et al., 2025).

Applications, Limits & Misconceptions

Crizotinib hydrochloride is a cornerstone reagent for:

• Dissecting ALK, c-Met, and ROS1-driven oncogenic signaling in cancer biology research.
• Modeling drug resistance in patient-derived assembloid and organoid systems (see prior review; this article details new assembloid data).
• Personalized drug screening and biomarker validation.
• Optimizing combinatorial therapy regimens in preclinical studies.

Common Pitfalls or Misconceptions

• Crizotinib hydrochloride is not selective for a single kinase; it targets ALK, c-Met, and ROS1 but may show off-target effects at high concentrations.
• It is not a pan-kinase inhibitor and should not be used to block all tyrosine kinase activity.
• Long-term storage of prepared solutions (>1 week) at room temperature may result in loss of potency; storage at -20°C is recommended (APExBIO).
• Monoculture systems may fail to reveal resistance mechanisms observable in stromal-rich assembloid models (Shapira-Netanelov et al., 2025).
• Clinical efficacy in vitro does not guarantee in vivo or clinical success due to tumor microenvironment complexity.

Workflow Integration & Parameters

Crizotinib hydrochloride (APExBIO SKU B3608) integrates flexibly into cancer research workflows. For optimal stability, dissolve in DMSO (≥100.4 mg/mL) and store aliquots at -20°C. Avoid repeated freeze-thaw cycles. Solutions in ethanol or water are also supported for specific assay requirements. In standard cell-based assays, effective concentrations range from 10–500 nM, with higher concentrations reserved for resistant models. For assembloid and organoid co-cultures, begin with 20–100 nM and titrate as needed to capture patient- or tissue-specific responses (see practical integration guidance—this article provides updated solubility and stability data). Quality assurance is critical: use only lots certified ≥98% purity by HPLC and NMR. Protocols for immunofluorescence and viability assays should include controls for solvent and time-matched vehicle.

For researchers seeking to understand tumor–stroma crosstalk, the use of Crizotinib hydrochloride in assembloid platforms—as described in recent peer-reviewed studies—provides unique insights not available from monoculture or traditional organoid systems (Shapira-Netanelov et al., 2025).

Detailed product information, technical data, and ordering options are available via APExBIO's Crizotinib hydrochloride page.

Conclusion & Outlook

Crizotinib hydrochloride is a rigorously validated, ATP-competitive ALK, c-Met, and ROS1 kinase inhibitor, enabling precise dissection of oncogenic signaling in advanced cancer models. Its robust activity, high solubility, and data-backed performance in assembloid systems position it as a pivotal tool for translational research and personalized medicine development. Ongoing advances in patient-derived tumor modeling and drug screening are likely to further expand its utility, especially as resistance mechanisms and tumor–stroma dynamics are increasingly understood. APExBIO continues to provide high-quality Crizotinib hydrochloride (SKU B3608) for research use worldwide.